Amber Uppal

Bachelor of Medicine and Bachelor of Science,  Toronto General - University Health Network 

Location: United States

Consulting Services

Research Consulting Pharma-CRO-Device

Areas Of Interest

Olfactory Bulb Antinematodal Agents Rubeomycin A Obstructions, Nasal Pain, Oncological Brown Coals Epilepsy, Immersion Related H-2D(b) Glycoprotein Structures, Mammalian Embryo Thapsia Chorea, Rheumatic Medicine, Pediatric Emergency Mesenchymal Stem Cell Articular Goniometry Receptors, PTS1 European Vipers Ion Channel, Chloride Therapies, Computer-Assisted Drug Behaviors, Obsessive FalisanNassbeize Nails Ataxin-3 Cranial Airocele Physical Anhedonias Leukotrienes A C3PA Convertase Cholinesterases Poliovirus Receptor-Related Protein 1 Oligozoospermia Agonists, Sodium Channel Transplantation, Renal Epilepsy, Anterior Fronto-Polar Schoenlein Henoch Purpura Hyssop, Water ortho-Iodohippurate gag-fos-fox Fusion Proteins

Professional Narrative

Dr. Amber Uppal was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Uppal has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.

Employment

Executive Director, Amgen 2018
Medical Writer, Harvard Med 1998

Education

Master of Science in physician assistant, Harvard Medical School 2011
Director Medicine, Weill Medical College 2005

Referees

Publications

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :

Languages

Language Proficiency :

Translation Services :

Serving Millions of physicians and biomedical scientists in Industry and academia.

Site
Services
Follow Us
Contact Us
  • support@scienceandminds.com

Copyright © 2025 Trialect Inc. All rights reserved. | v2023.06.17.02